Pages that link to "Q37833005"

The following pages link to Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities (Q37833005):

Displaying 34 items.

• Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies (Q27002547) (← links)
• Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation (Q33684263) (← links)
• Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma (Q33757003) (← links)
• EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma (Q34738001) (← links)
• Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer (Q35150642) (← links)
• Molecular characterization of gallbladder cancer using somatic mutation profiling (Q35597012) (← links)
• BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer (Q35674192) (← links)
• Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer (Q35696749) (← links)
• Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping (Q35705307) (← links)
• Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma (Q35840582) (← links)
• Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. (Q36414244) (← links)
• Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice (Q36544718) (← links)
• Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing (Q36870198) (← links)
• Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells (Q37709171) (← links)
• The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma (Q37964960) (← links)
• Gallbladder cancer: can newer insights improve the outcome? (Q37968331) (← links)
• Chemotherapy for the biliary tract cancers: moving toward improved survival time (Q37983498) (← links)
• Potential biomarkers in gallbladder cancer: present status and future directions (Q38038882) (← links)
• Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis (Q38148062) (← links)
• Immunotherapy of biliary tract cancer (Q38686339) (← links)
• Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway (Q38949695) (← links)
• Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescence (Q38970720) (← links)
• Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma (Q39179249) (← links)
• Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. (Q39312152) (← links)
• Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies (Q42272472) (← links)
• Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer (Q43646189) (← links)
• Selection and identification of novel peptides specifically targeting human cervical cancer. (Q50051258) (← links)
• Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances (Q50173842) (← links)
• Platelet-derived growth factor D: a new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts. (Q50972322) (← links)
• Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. (Q55497250) (← links)
• Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) (Q57118798) (← links)
• Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer (Q59126036) (← links)
• Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma (Q64229475) (← links)
• Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases (Q91906078) (← links)